PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
7864430-6	1995	Although there were no significant differences in catecholamine levels, plasma renin activity was significantly increased at postincision in the preoperative-enalaprilat group versus the placebo group.	Enalaprilat	158-169	renin	Homo sapiens	79-84	
2559850-0	1989	Coronary vasodilation induced by intracoronary enalaprilat: an argument for the role of a local renin-angiotensin system in patients with dilated cardiomyopathy.	Enalaprilat	47-58	renin	Homo sapiens	96-101	
7994817-7	1994	Effective inhibition of the renin-angiotensin system by remikiren and enalaprilat was indicated by increases of plasma immunoreactive renin together with rapid and complete inhibition of renin activity after remikiren and an increase after enalaprilat (all P < or = .05).	Enalaprilat	70-81	renin	Homo sapiens	28-33	
7994817-7	1994	Effective inhibition of the renin-angiotensin system by remikiren and enalaprilat was indicated by increases of plasma immunoreactive renin together with rapid and complete inhibition of renin activity after remikiren and an increase after enalaprilat (all P < or = .05).	Enalaprilat	70-81	renin	Homo sapiens	134-139	
7994817-7	1994	Effective inhibition of the renin-angiotensin system by remikiren and enalaprilat was indicated by increases of plasma immunoreactive renin together with rapid and complete inhibition of renin activity after remikiren and an increase after enalaprilat (all P < or = .05).	Enalaprilat	70-81	renin	Homo sapiens	134-139	
7994817-7	1994	Effective inhibition of the renin-angiotensin system by remikiren and enalaprilat was indicated by increases of plasma immunoreactive renin together with rapid and complete inhibition of renin activity after remikiren and an increase after enalaprilat (all P < or = .05).	Enalaprilat	240-251	renin	Homo sapiens	28-33	
7994817-8	1994	Remikiren and enalaprilat rapidly and to a similar extent reduced resting blood pressure through a reduction of systemic vascular resistance, and these changes were significantly correlated to baseline plasma renin activity.	Enalaprilat	14-25	renin	Homo sapiens	209-214	
1657799-0	1991	Enalaprilat in acute myocardial infarction: tolerability and effects on the renin-angiotensin system.	Enalaprilat	0-11	renin	Homo sapiens	76-81	
1646164-6	1991	After enalaprilat, norepinephrine venoarterial difference increased in the renin-secreting kidney (from 264 to 396, SED = 57 pg/ml, p less than 0.05), whereas it increased only slightly in the contralateral kidney (from 149 to 256, SED = 72 pg/ml, NS).	Enalaprilat	6-17	renin	Homo sapiens	75-80	
2559850-5	1989	Despite these steady haemodynamic conditions, intracoronary enalaprilat provoked a significant elevation of coronary sinus blood flow (181 +/- 73 to 214 +/- 79 ml min-1, P less than 0.001) with a reduction of coronary resistance (0.51 +/- 0.17 to 0.41 +/- 0.15 mmHg ml-1 min, P less than 0.001), and no significant alteration in plasma renin activity or plasma aldosterone.	Enalaprilat	60-71	renin	Homo sapiens	336-341	
3023555-6	1986	Intravenous enalaprilat stimulated plasma renin activity and decreased immunoreactive plasma angiotensin II and plasma aldosterone concentrations.	Enalaprilat	12-23	renin	Homo sapiens	42-47	
2834938-0	1988	Unrelated responses of brachial artery hemodynamics and renin-angiotensin system to acute converting enzyme inhibition by enalaprilat in essential hypertension.	Enalaprilat	122-133	renin	Homo sapiens	56-61	
2834938-1	1988	The simultaneous acute effects of converting enzyme inhibition by intravenous enalaprilat on the circulating renin-angiotensin system and on the brachial artery were studied in 12 hypertensive patients by a double-blind comparison with saline effects in 14 hypertensive patients.	Enalaprilat	78-89	renin	Homo sapiens	109-114	
2834938-4	1988	Compared with the saline vehicle, enalaprilat significantly decreased angiotensin enzyme converting activity (p less than 0.001), increased plasma renin activity (p less than 0.01) and decreased plasma aldosterone concentrations (p less than 0.01).	Enalaprilat	34-45	renin	Homo sapiens	147-152	
2843688-1	1988	The effectiveness of 2 angiotensin converting enzyme inhibitors, intravenous enalaprilat and oral captopril, in stimulating renin secretion was compared in 47 hypertensive patients with suspected renovascular hypertension.	Enalaprilat	77-88	renin	Homo sapiens	124-129	
2843688-9	1988	Plasma renin activity increased by 5 and 15 minutes with enalaprilat and captopril, respectively.	Enalaprilat	57-68	renin	Homo sapiens	7-12	
21795644-4	2011	In contrast, two- and threefold disease-induced increases in renin mRNA and activity were further increased 2- and 3.7-fold with 10(-4) M enalaprilate treatment.	Enalaprilat	138-150	renin	Homo sapiens	61-66	
28356668-4	2017	We report two pediatric cases of atypical HUS with severe refractory malignant hypertension, in which we targeted the renin-angiotensin system by using intravenous (IV) enalaprilat, oral aliskiren, and oral enalapril with quick and dramatic response of blood pressure.	Enalaprilat	169-180	renin	Homo sapiens	118-123	
21795644-5	2011	Depressing the renin receptor by 80% with small interfering (si) RNA alone reduced fibrotic markers in a manner remarkably similar to enalaprilate alone but had no effect on glomerular renin expression.	Enalaprilat	134-146	renin	Homo sapiens	15-20